| ［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］.CA Cancer J Clin, 2011, 61(2):69-90.
［2］ Klein EA, Silverman R. Inflammation, infection, and prostate cancer［J］. Curr Opin Urol, 2008, 18(3):315-319.
［3］ Robbins CM, Hernandez W, Ahaghotu C, et al. Association of HPC2/ELAC2 and RNASEL nonsynonymous variants with prostate cancer risk in African American familial and sporadic cases［J］. Prostate, 2008, 68 (16):1790-1797.
［4］ Rennert H, ZeiglerJohnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men［J］. Cancer Epidemiol Biomarkers Prev, 2005, 14(4):949-957.
［5］ Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans［J］. Clin Cancer Res, 2007, 13(19):5959-5964.
［6］ Nakazato H, Suzuki K, Matsui H, et al. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population［J］. Br J Cancer, 2003, 89(4):691-696.
［7］ Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p［J］. Nat Genet, 2001, 27(2):172-180.
［8］ Wang L, McDonnell SK, Elkins DA, et al. Role of HPC2/ELAC2 in hereditary prostate cancer［J］. Cancer Res, 2001, 61(17):6494-6499.
［9］ Xu B, Tong N, Li JM, et al. ELAC2 polymorphisms and prostate cancer risk: a metaanalysis based on 18 casecontrol studies［J］. Prostate Cancer Prostatic Dis, 2010, 13(3):270-277.
［10］ Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis［J］. Cancer Res, 2010, 70(13):5207-5212.
［11］ Liu W, Chang B, Sauvageot J, et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100KSNP mapping array［J］. Genes Chromosomes Cancer, 2006, 45(11):1018-1032.
［12］ Haiman CA, Stram DO, Cheng I, et al. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer［J］. Cancer Epidemiol Biomarkers Prev, 2006, 15(5):1021-1025.
［13］ Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk［J］. Nat Genet, 2002, 32(2):321-325.
［14］ Seppl EH, Ikonen T, Autio V, et al. Germline alterations in MSR1 gene and prostate cancer risk［J］. Clin Cancer Res, 2003, 9(14):5252-5256.
［15］ Sun J, Hsu FC, Turner AR, et al. Metaanalysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk［J］. Prostate, 2006, 66(7):728-737.
［16］ Ren S, Peng Z, Mao JH, et al. RNAseq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancerassociated long noncoding RNAs and aberrant alternative splicings［J］. Cell Res, 2012, 22(5):806-821.
［17］ Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2ERG fusion prostate cancer among men undergoing prostate biopsy in the United States［J］. Clin Cancer Res, 2009, 15(14):4706-4711.
［18］ Miyagi Y, Sasaki T, Fujinami K, et al. ETS familyassociated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples［J］. Mod Pathol, 2010, 23(11):1492-1498.
［19］ MagiGalluzzi C, Tsusuki T, Elson P, et al. TMPRSS2ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, AfricanAmerican and Japanese patients［J］. Prostate, 2011, 71(5):489-497.
［20］ Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusionassociated deletions provide insight into the heterogeneity of prostate cancer［J］. Cancer Res, 2006, 66(17): 8337-8341.
［21］ Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2ERG gene fusion is associated with low Gleason scores and not with highgrade morphological features［J］. Mod Pathol, 2010, 23(10):1325-1333.
［22］ Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort［J］. Oncogene, 2007, 26(31):4596-4599.
［23］ Winnes M, Lissbrant E, Damber JE, et al. Molecular genetic analyses of the TMPRSS2ERG and TMPRSS2ETV1 gene fusions in 50 cases of prostate cancer［J］. Oncol Rep, 2007, 17(5):1033-1036.
［24］ Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome［J］. Mod Pathol, 2008, 21(12):1451-1460.
［25］ Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2ERG gene fusion is not associated with outcome in patients treated by prostatectomy［J］. Cancer Res, 2009, 69(4):1400-1406. |
